Cronos News

Please Note: Press releases contained on this website are for historical purposes only and that while information contained within the releases was believed to be accurate at the time of issue, the Company will not, and specifically disclaims any duty to, update this information.

Conference Call

Cronos Group will host a conference call and webcast today, Friday, December 7 at 8:30 a.m. ET to discuss today’s announcement.

Toll-free dial-in number: (888) 231-8191
International dial-in number: (647) 427-7450
Conference ID: 9359909

A replay of the conference call will be available for approximately two weeks, from December 7, 2018 through December 21, 2018, and can be accessed by dialing (855) 859-2056 and providing the 9359909 confirmation code.

Toll-free dial-in number: (855) 859-2056
Passcode: 9359909

Conference Call

Cronos Group will host a conference call and webcast today, Friday, December 7 at 8:30 a.m. ET to discuss today’s announcement.

Toll-free dial-in number: (888) 231-8191
International dial-in number: (647) 427-7450
Conference ID: 9359909

A replay of the conference call will be available for approximately two weeks, from December 7, 2018 through December 21, 2018, and can be accessed by dialing (855) 859-2056 and providing the 9359909 confirmation code.

Toll-free dial-in number: (855) 859-2056
Passcode: 9359909

Cronos Group Inc. Announces C$2.4 Billion Strategic Investment from Altria Group, Inc

Cronos Group Inc. today announced that it has entered into a subscription agreement with Altria Group, Inc. pursuant to which Altria has agreed to make an approximately C$2.4 billion equity investment in Cronos Group on a private placement basis in exchange for common shares in the capital of the Company. Altria will also receive Warrants of Cronos Group, that if fully exercised, would provide the Company with an additional approximately C$1.4 billion of proceeds. The Shares issuable to Altria pursuant to the Subscription Agreement will result in Altria holding an approximately 45% ownership interest in Cronos Group (calculated on a non-diluted basis), exercise of the Warrants would result in incremental ownership of 10% for a total potential ownership position of 55%. This strategic partnership provides Cronos Group with additional financial resources, product development and commercialization capabilities, and deep regulatory expertise to better position the Company to compete, scale and lead the rapidly growing global cannabis industry.

read more

Cronos Group Inc. Announces Third Quarter 2018 Results

“We are encouraged with our third quarter results, which reflect the meaningful progress we are making on our strategic initiatives. In the quarter, we announced a number of landmark partnerships to expand our reach beyond the flower and beyond Canada and launched our second differentiated recreational cannabis brand,” said Mike Gorenstein, CEO of Cronos Group.

read more

Cronos Group Inc. to Hold Third Quarter 2018 Earnings Conference Call

Cronos Group, a geographically diversified and vertically integrated cannabis group, will announce its financial results and hold its Third Quarter 2018 Earnings Conference Call on Tuesday, November 13, 2018 at 8:30 a.m. EDT. Senior management will be available for questions from the investment community after prepared remarks.

read more

Cronos Group Inc. Launches New Recreational Brand Spinach

Spinach™ is focused on offering Farm-To-Bowl™ products that bring friends together and make experiences more enjoyable. Spinach™ has selected some of the most popular strains from Cronos Group’s genetic library because when you’re having fun, you should never have to worry about the quality of your Spinach™. Harmful additives don’t have a place in good Spinach™, which is why quality control is the only think we take seriously. More information on how to Get-Your-Greens™ can be found at www.spinachcannabis.com. Warning: Spinach™ may be a gateway to pizza

read more

A Landmark Partnership to Produce Cultured Cannabinoids

Leading Companies from Emerging Industries Join Forces to Efficiently Produce High-Purity Cannabinoids at Scale.
Today, Cronos Group Inc. and Ginkgo Bioworks Inc. announced a landmark partnership to produce cultured cannabinoids. Using its platform technology for organism design and development, Ginkgo will complement Cronos Group’s technologies for producing a full spectrum of cannabinoids. As part of this unprecedented deal, Cronos Group has agreed to issue a specific number of common shares in tranches subject to Ginkgo’s achievement of certain production milestones.

read more

Cronos Group Inc. Unveils Platform in LATAM

Cronos Group Inc., is pleased to announce that it has entered into a joint venture agreement with an affiliate of Agroidea SAS (“AGI”), Colombia’s leading agricultural services provider with over 30 years of research, development and production operations. This partnership establishes a newly formed entity, NatuEra S.à r.l. (“NatuEra”), in Colombia that will develop, cultivate, manufacture and export cannabis-based medicinal and consumer products for the Latin American and global markets.

read more

Cronos Group Inc. Announces Provincial Supply Agreements

Cronos Group has secured listings and signed binding master supply agreements with both the Ontario Cannabis Retail Corporation and the BC Liquor Distribution Branch. In combination, these provinces encompass over 50% of the Canadian population and hence the potential customer base which the Company is prepared to serve.

read more

Cronos Group Inc. Announces Second Quarter 2018 Results

“This year and subsequently, this quarter is about setting the stage and establishing Cronos Group’s strategy for future growth,” said Mike Gorenstein, CEO of Cronos Group. “Cronos Group delivered encouraging results across the Company in the second quarter with sales growing among all of our products and channels, impressive improvements in cultivation yields since the start of the year, and continued business development success in penetrating new markets and establishing new partnerships for expansion.”

read more

Cura Goes International with Cronos Group Inc.

Cronos Group Inc., is pleased to announce that it has entered into a supply agreement with one of the largest cannabis companies in the world by revenue in the first quarter of 2018, Cura Select Canada, Ltd. Cura is on a mission to be the leading provider of premium cannabis oil and hemp oil to the legal U.S. and international markets, and will enter the Canadian market to supply domestic and international channels.

read more

Cronos Group Inc. Announces Results of Vote for Election of Directors

(“Cronos Group” or the “Company”), a geographically diversified and vertically integrated cannabis group, reports that at its Annual and Special Meeting of Shareholders on June 28, 2018 there were 658 shareholders voting in person and by proxy holding in total 92,611,201 common shares, representing 52.56% of the total number of common shares outstanding.

read more

Cronos Australia is Granted Manufacturing License

(“Cronos Group” or the “Company”), is pleased to announce that Cronos Australia Pty Ltd. (“Cronos Australia”) has been granted a medicinal cannabis Manufacture License by the Australian Office of Drug Control.

read more

Cronos Group Inc. Announces Fourth Quarter and Fiscal Year 2017 Results

Cronos Group Inc. today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.
“We are building Cronos Group with a focus on the long-term and 2017 set the foundation for the explosive growth we have already started realizing in 2018,” said Mike Gorenstein,” CEO of Cronos Group.  “We are extremely proud of all that our team has accomplished and look forward to a year of rapid increases in sales, commencing distribution in new markets, further developing disruptive intellectual property and launching new iconic brands.”

read more

Cronos Group Inc. Announces $100 Million Bought Deal

Cronos Group is pleased to announce that it has entered into an agreement with a syndicate of underwriters co-led by GMP Securities L.P. and BMO Capital Markets to sell 10,420,000 common shares (11,983,000 common shares if the over-allotment described below is exercised in full) of the Company, on a “bought deal” basis, at a price of $9.60 per common share, for gross proceeds of approximately $100.0 million (approximately $115.0 million if the over-allotment option is exercised in full).

read more

Cannabis Giants Join Forces in Cross Border Venture

With Canada on track to legalize adult use of cannabis, two of the world’s largest cannabis companies announced a first-of-its-kind cross border joint venture today that could bring America’s most recognized cannabis brand to Canadian consumers by year’s end.

read more

Cronos Group Changes Canadian Ticker to CRON

Cronos Group Inc. is pleased to announce that the Company is changing its ticker on the TSX Venture Exchange from MJN to CRON. This change is effective immediately for trading commencing on Monday, March 5 and is being made to conform to the ticker symbol that was selected when Cronos Group became the first pure-play cannabis company to trade on the Nasdaq on February 27, 2018

read more

Cronos Group to Begin Trading on NASDAQ Stock Exchange

Cronos Group Inc. (TSX-V: MJN) (OTC Nasdaq Int’l Designation: PRMCF) is pleased to announce that trading of its common shares in the United States will be elevated from the Nasdaq International Designation program to the Nasdaq Global Market. Cronos Group expects that its common shares will begin trading on Nasdaq on February 27, 2018 under the trading ticker symbol “CRON.” Cronos Group will retain its listing on the TSX Venture Exchange under the symbol “MJN.”

read more

Cronos Group Announces Launch of Cronos Australia with Grant of Two Licenses

Cronos Australia is a 50/50 joint venture between the Group and NewSouthern Capital Pty Ltd, led by Mr. Rodney Cocks and Mr. Peter Righetti.  Cronos Australia will serve as the Group’s hub for Australia, New Zealand, and South East Asia, bolstering the Group’s import/export supply capabilities and distribution network.  Cronos Australia will leverage the Group’s intellectual property and iconic brands to deliver premium cannabinoid based products to Australasia.

read more

Cronos Group Announces Closing of Previously Announced $46 Million Bought Deal

(“Cronos Group” or the “Company”) is pleased to announce that it has closed its previously announced bought deal public offering, including the full exercise of the over-allotment option. As such, a total of 5,257,143 common shares of Cronos Group (the “Shares”) were sold at a price of $8.75 per Share for aggregate gross proceeds of approximately $46.0 million (the “Offering”).

read more

Cronos Group Inc. Announces $30 Million Bought Deal

Cronos Group Inc. is pleased to announce that it has entered into a letter of engagement with PI Financial Corp. as lead underwriter on behalf of a syndicate of underwriters under which the Underwriters have agreed to purchase for re-sale 3,428,572 common shares of the Company.

read more

Cronos Press Release – Q3 2017 Financial Results

Cronos Group today reported financial results for the third quarter ended September 30, 2017.  Financial results and the management discussion and analysis are available on the Company’s website and SEDAR (www.sedar.com).

read more
Cronos Rebrands Recreational Platform

Cronos Rebrands Recreational Platform

OGBC is located on 31 acres of land in the Okanagan Valley in British Columbia and is focused on quality and integrity, committed to continuing BC’s long history of producing some of the world’s finest cannabis

read more

Cronos Announces Upsizing of Private Placement of Common Shares

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES TORONTO, Sept. 18, 2017 /CNW/ - Further to its press release on September 14, 2017, Cronos Group Inc. ("Cronos" or the "Company") (TSX Venture: MJN) (OTC – Nasdaq International...

read more

Cronos Announces Private Placement of Common Shares

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES TORONTO, Sept. 14, 2017 /CNW/ - Cronos Group Inc. ("Cronos" or the "Company") (TSX Venture: MJN) (OTC – Nasdaq International Designation: PRMCF) is pleased to announce that it...

read more

Cronos Receives Nasdaq International Designation

TORONTO, Sept. 12, 2017 /CNW/ - Cronos Group Inc. (TSXV: MJN) (OTC: PRMCF) ("Cronos" or the "Company") is pleased to announce that it is the first cannabis company to be admitted into the Nasdaq International Designation program under the symbol OTC – Nasdaq...

read more

Cronos Establishes International Low Cost Production in Israel

TORONTO, Sept. 6, 2017 /CNW/ - Cronos Group Inc. (TSXV: MJN) (OTC: PRMCF) ("Cronos" or the "Company") is pleased to announce that the Company has entered into a strategic joint venture ("Cronos Israel") with Kibbutz Gan Shmuel ("Gan Shmuel") for the production,...

read more

Q2 2017 Financial Results and Provides Operational Update

TORONTO, Aug. 28, 2017 /CNW/ - Cronos Group Inc. (TSXV:MJN) (OTC: PRMCF) ("Cronos" or the "Company") is pleased to report the financial results and accompanying management discussion and analysis for the quarter ending June 30, 2017; copies are available on the...

read more

Cronos Group Secures $40M in Debt for Domestic Capacity Expansion

TORONTO, Aug. 24, 2017 /CNW/ – Cronos Group Inc. is announcing today that it has entered into a commitment letter for $40 million in debt financing with Romspen Investment Corporation (“Romspen”) to fund the continued construction of its 315,000 sq. ft. expansion (the “New Peace Facility”) previously outlined in the Company’s press release dated May 23, 2017.

read more

Cronos Group Files Q1 2017 Financial Results

TORONTO, May 30, 2017 /CNW/ - Cronos Group Inc. (TSX VENTURE: MJN) ("Cronos" or the "Company") is pleased to report the financial results and accompanying management discussion and analysis for the quarter ending March 31, 2017; copies are available on the Company's...

read more

Cronos Group Responds to Health Canada Testing

TORONTO, May 5, 2017 /CNW/ - Cronos Group Inc.'s (TSXV:MJN) wholly owned licensed producer, the Peace Naturals Project Inc. ("Peace"), was notified on May 4, 2017 by Health Canada that upon testing a random cannabis leaf sample, trace levels of Piperonyl Butoxide...

read more

Cronos Group Provides Update on Minority Investments

TORONTO, ON--(Marketwired - April 24, 2017) Cronos Group Inc. (formerly PharmaCan Capital Corp.) (TSX VENTURE: MJN) ("Cronos", or the "Company") is providing an update on its investments in Whistler Medical Marijuana Corporation ("Whistler"), The Hydropothecary...

read more

Cronos Recognized as Top TSX Venture 50 Performer

TORONTO, Feb. 27, 2017 /CNW/ - Cronos Group Inc., formerly PharmaCan Capital Corp., (TSX VENTURE: MJN) ("Cronos Group" or "the Company"), is excited to announce the Company's recent recognition as the top performer in the 2017 TSX Venture 50, an award reserved for the...

read more

PharmaCan Capital Announces $15 Million Bought Deal

        TORONTO, ONTARIO--(Marketwired - Feb. 14, 2017) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE:MJN) ("Cronos" or the "Company") is pleased...

read more

Cronos Calls Shareholder Meeting to Formalize Name Change

        TORONTO, ON--(Marketwired - January 23, 2017) PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or the "Company"), seeks shareholder approval to formally change its name to "Cronos Group Inc." following the corporate...

read more

Cronos Group Granted Second Health Canada Sales License

TORONTO, ON--(Marketwired - January 11, 2017) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or the "Company"), is pleased to announce that the...

read more

Cronos Enters Exclusive European Supply Agreement with Pedanios

TORONTO, ON - (Marketwired - December 28, 2016) PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or "the Company"), is pleased to announce the execution of an exclusive supply agreement with German-based Pedanios GmbH ("Pedanios")...

read more

Cronos Group Provides Operational Update and Q3 Financial Results

TORONTO, ON –November 29, 2016 NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE PharmaCan Capital Corp., doing business as Cronos Group (TSXV:MJN) (“Cronos” or the “Company”) is pleased to provide the first operational update related to its...

read more

Cronos Group Grants Stock Options

TORONTO, ONTARIO--(Marketwired - Nov. 21, 2016) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES PharmaCan Capital Corp. doing business as Cronos Group ("Cronos Group" or the "Company") (TSX VENTURE:MJN) announces it has granted...

read more

Cronos Group Receives Liquidity From Non-Core Asset

TORONTO, ON--(Marketwired - November 01, 2016) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos Group" or "the Company"), has divested its equity...

read more

PharmaCan announces corporate rebranding to become Cronos Group

PharmaCan Capital today announced a corporate rebranding to Cronos Group. This rebranding reflects the new strategic vision of the Company as Canada’s first bi-coastal licensed cannabis producer with interests in five Licensed Producers (“LPs”) and three license applicants.

read more

Financial Statements

Unaudited Consolidated Financial reports and Management’s Discussion and Analysis reports for Cronos Group will be posted here quarterly. Please visit SEDAR for a complete listing of corporate filings and archived filings for Cronos Group Inc.

Financial Statements

Unaudited Consolidated Financial reports and Management’s Discussion and Analysis reports for Cronos Group will be posted here quarterly. Please visit SEDAR for a complete listing of corporate filings and archived filings for Cronos Group Inc.

2017
2017 – Q1 Interim Condensed Financial Statements 2017 – Q1 Management’s Discussion and Analysis (MD&A) 2017 – Q2 Interim Condensed Financial Statements 2017 – Q2 Management’s Discussion and Analysis (MD&A) 2017 – Q3 Interim Condensed Financial Statements 2017 – Q3 Management’s Discussion and Analysis (MD&A) 2017 – Annual Information Form  PDF 2017 – Year End Consolidated Financial Statements  PDF 2017 – Year End Management’s Discussion and Analysis (MD&A)  PDF Year End Notice of Record and Meeting Date  PDF ______________________________________________ XBRL Instance Document (XML) XBRL Taxonomy Extension Calculation Linkbase (XML) XBRL Taxonomy Extension Definition Linkbase (XML) XBRL Taxonomy Extension Label Linkbase (XML) XBRL Taxonomy Extension Presentation Linkbase (XML) XBRL Taxonomy Extension Schema (XSD)

720 King Street West, Suite 320

Toronto, Ontario M5V 2T3

Info@TheCronosGroup.com
Careers@TheCronosGroup.com

(416) 504-0004